Related Experiment Video
Updated: Sep 23, 2025
Stem Cell Transplantation Strategies for the Restoration of Cognitive Dysfunction Caused by Cranial Radiotherapy
Published on: October 18, 2011
A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology
Michael A Vogelbaum1, Gongbo Li2, Amy B Heimberger2
1Department of NeuroOncology and NeuroOncology Program, Moffitt Cancer Center, Tampa, FL.
Abstract:
Glioblastoma is the most common primary malignant brain neoplasm and it remains one of the most difficult-to-treat human cancers despite decades of discovery and translational and clinical research. Many advances have been made in our understanding of the genetics and epigenetics of gliomas in general; yet, there remains an urgent need to develop novel agents that will improve the survival of patients with this deadly disease. What sets glioblastoma apart from all other cancers is that it develops and spreads within an organ that renders tumor cells inaccessible to most systemically administered agents because of the presence of the blood-brain barrier. Inadequate drug penetration into the central nervous system is often cited as the most common cause of trial failure in neuro-oncology, and even so-called brain-penetrant therapeutics may not reach biologically relevant concentrations in tumor cells. Evaluation of the pharmacokinetics and pharmacodynamics of a novel therapy is a cornerstone of drug development, but few trials for glioma therapeutics have incorporated these basic elements in an organ-specific manner. Window-of-opportunity clinical trial designs can provide early insight into the biological plausibility of a novel therapeutic strategy in the clinical setting. A variety of window-of-opportunity trial designs, which take into account the limited access to treated tissue and the challenges with obtaining pretreatment control tissues, have been used for the initial development of traditional and targeted small-molecule drugs and biologic therapies, including immunotherapies and oncolytic viral therapies. Early-stage development of glioma therapeutics should include a window-of-opportunity component whenever feasible.
Insights
Developing novel treatments for glioblastoma (GBM) is critical due to the blood-brain barrier limiting drug efficacy. Window-of-opportunity trials offer a promising approach to assess new GBM therapies effectively.
Area of Science:
- Neuro-oncology
- Malignant Brain Neoplasms
- Pharmacokinetics and Pharmacodynamics
Background:
- Glioblastoma (GBM) is the most prevalent primary malignant brain tumor, notoriously difficult to treat.
- The blood-brain barrier (BBB) significantly impedes systemic drug delivery to brain tumors, a major cause of treatment failure.
- Existing research highlights an urgent need for novel therapeutic agents to improve survival rates for GBM patients.
Purpose of the Study:
- To emphasize the necessity of evaluating novel therapeutic agents for glioblastoma.
- To highlight the challenges posed by the blood-brain barrier in treating brain tumors.
- To advocate for the integration of window-of-opportunity clinical trial designs in early-stage glioblastoma drug development.
Main Methods:
- Discusses the challenges in assessing drug pharmacokinetics and pharmacodynamics in the central nervous system (CNS).
- Explains the utility of window-of-opportunity (WOO) trial designs in overcoming limitations of traditional clinical trials for brain tumors.
- Reviews various WOO trial designs adapted for evaluating small-molecule drugs, biologics, immunotherapies, and oncolytic viruses in glioma.
Main Results:
- Inadequate drug penetration into the CNS is a primary reason for clinical trial failures in neuro-oncology.
- Even 'brain-penetrant' drugs may not achieve sufficient concentrations within tumor cells.
- WOO trials can provide crucial early insights into the biological activity and feasibility of novel therapeutic strategies within the clinical context.
Conclusions:
- Window-of-opportunity trials are valuable for assessing novel glioblastoma therapeutics, considering CNS drug delivery challenges.
- These trial designs can accommodate limitations in accessing treated tumor tissue and obtaining pre-treatment controls.
- Incorporating WOO components into early-stage glioblastoma therapeutic development is highly recommended whenever feasible.
Related Concept Videos
02:56Treatment Resistant Cancers
01:23Techniques of Therapeutic Communication II: Focusing, Paraphrasing, and Summarizing
This therapeutic technique can also be used when a patient brings up pertinent information during a health-related conversation. The...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:25Elements Crucial for Effective Psychotherapy
The Therapeutic Alliance
The therapeutic alliance refers to the relationship between the therapist and the client. The alliance strengthens when the therapist and the client engage in a nurturing, supportive, trusting, empathetic, and respectful relationship, improving therapeutic outcomes. Therapists must monitor this relationship...
01:27Tumor Immunotherapy